Company
Nuvaira
Innovative COPD therapies to help preserve patient lung health with a catheter-based system used to treat overactive airways.
Also known as Nuvaira Inc
- Business model
- B2B
- Legal name
- Nuvaira Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Nuvaira is developing a first-in-class bronchoscopic device and procedure to treat lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
Funding snapshot
- Total raised
- $178MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $35.8M2026-02-20
Funding rounds
- Round, 2026
- $35.8M2026-02-20, SEC form D sold, 9 investors
- Round, 2025
- $979K2025-08-11, SEC form D sold, 8 investors
- Round, 2024
- $52.9K2024-04-24, SEC form D sold, 13 investors
- Round, 2023
- $15.1M2023-11-28, SEC form D sold, 39 investors
- Round, 2020
- $31.3M2020-07-13, SEC form D sold, 49 investors
- Round, 2019
- $25M2019-02-07, SEC form D sold, 20 investors
- Round, 2018
- $4M2018-04-06, SEC form D sold, 9 investors
- Round, 2014
- $42M2014-04-02, SEC form D sold, 9 investors
- Round, 2013
- $10M2013-02-08, SEC form D sold, 5 investors
- Round, 2012
- $10.6M2012-03-23, SEC form D sold, 16 investors
- Round, 2010
- $3M2010-09-15, SEC form D sold, 3 investors
- Round, 2009
- $83.1K2009-03-31, SEC form D sold, 3 investors
Loading relationship preview